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Abstract
Complement plays a crucial role in microbial defense and clearance of apoptotic cells. Emerging evidence suggests
complement is an important contributor to alcoholic liver disease. While complement component 1, Q subcomponent
(C1q)-dependent complement activation contributes to ethanol-induced liver injury, the role of the alternative
pathway in ethanol-induced injury is unknown. Activation of complement via the classical and alternative pathways
was detected in alcoholic hepatitis patients. Female C57BL/6J [wild type (WT)], C1q-deficient (C1qa , lacking
classical pathway activation), complement protein 4-deficient (C4 , lacking classical and lectin pathway activation),
complement factor D-deficient (FD , lacking alternative pathway activation), and C1qa/FD  (lacking classical
and alternative pathway activation) mice were fed an ethanol-containing liquid diet or pair-fed control diet for 4 or 25
days. Following chronic ethanol exposure, liver injury, steatosis, and proinflammatory cytokine expression were
increased in WT but not C1qa , C4 , or C1qa/FD  mice. In contrast, liver injury, steatosis, and
proinflammatory mediators were robustly increased in ethanol-fed FD  mice compared with WT mice.
Complement activation, assessed by hepatic accumulation of C1q and complement protein 3 (C3) cleavage products
(C3b/iC3b/C3c), was evident in livers of WT mice in response to both short-term and chronic ethanol. While C1q
accumulated in ethanol-fed FD  mice (short term and chronic), C3 cleavage products were detected after short-term
but not chronic ethanol. Consistent with impaired complement activation, chronic ethanol induced the accumulation
of apoptotic cells and fibrogenic responses in the liver of FD  mice. These data highlight the protective role of
complement factor D (FD) and suggest that FD-dependent amplification of complement is an adaptive response that
promotes hepatic healing and recovery in response to chronic ethanol.
NEW & NOTEWORTHY Complement, a component of the innate immune system, is an important
pathophysiological contributor to ethanol-induced liver injury. We have identified a novel role for factor D, a
component of the alternative pathway, in protecting the liver from ethanol-induced inflammation, accumulation of
apoptotic hepatocytes, and profibrotic responses. These data indicate a dual role of complement with regard to
inflammatory and protective responses and suggest that accumulation of apoptotic cells impairs hepatic
healing/recovery during alcoholic liver disease.
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INTRODUCTION
Alcohol is a leading cause of preventable morbidity and mortality worldwide (11, 30). Chronic alcohol abuse
underlies the pathogenesis of alcoholic liver disease (ALD), encompassed by a spectrum of pathologies, ranging from
steatosis to more severe forms of liver injury, including alcoholic hepatitis (AH), fibrosis, and cirrhosis. AH, an
inflammatory condition characterized by infiltration of leukocytes and hepatocellular injury, remains an important
contributor to mortality from ALD (16). Twenty-eight-day mortality rates for severe AH remain between 25 and 35%,
and there remains no consensus regarding the preferred first-line treatment option for AH (22). Moreover, ~70% of
individuals who develop AH will progress to cirrhosis (44). While current therapies focus on suppressing
inflammation, they are relatively ineffective in patients with severe AH, and outcomes remain poor (11, 19, 57).
The innate immune system is an important contributor to the pathogenesis of ALD. Multiple components of the
innate immune response, including hepatic macrophages and cytokine/chemokine networks, are impacted by alcohol
and contribute to a dysregulated innate immune environment (3, 12). Persistent activation of the innate immune
system by alcohol in turn contributes to excessive cell death of hepatocytes, by both apoptosis and necroptosis, and
drives further hepatic tissue injury. Repeated cycles of cell damage and further stimulation of the innate immune
response contributes to nonresolving inflammation in patients with AH (28).
Recent studies have also implicated complement as an important pathophysiological contributor to ethanol-induced
liver injury. Complement, a component of the innate and adaptive immune system, plays a crucial role in microbial
defense and clearance of apoptotic cells, but aberrant uncontrolled activation of complement causes extensive tissue
injury (17, 37). Complement is activated by three pathways, the classical, lectin, and alternative pathways. Classical
pathway activation is initiated upon the binding of complement component 1, Q subcomponent (C1q), the recognition
subunit of the first component (C1), to antigen-antibody complexes while lectin pathway activation occurs via
pathogenic recognition by mannose-binding lectin and ficolin (31). Both the classical and lectin pathways converge at
complement protein 4 (C4), leading to downstream cleavage of complement protein 3 (C3). The alternative pathway
provides amplification and low-level continuous formation of a soluble C3 convertase that associates with factor B
(FB); factor D (FD) serves to activate this self-amplification loop, termed the “tick-over” pathway of complement
activation, providing a state of complement “alertness” (29, 37).
Understanding the role of complement in the development of ALD has been a central research focus in the last
decade. Complement is activated in mouse models of ALD (mALD); accumulation of C1q and C3 cleavage products
(C3b/iC3b/C3c) can be detected in the liver (9, 40, 47), and serum levels of the anaphylatoxin fragment of C3 (C3a)
are elevated (33). Expression of C1q, C3, C5, and anaphylatoxin fragment of C5 (C5a) receptor (C5aR) is elevated in
livers of AH patients (46). In murine models of ALD, C5  mice are protected from ethanol-induced elevations of
plasma alanine transaminase (ALT) and hepatic cytokine production while C3  mice are protected from steatosis
following chronic ethanol feeding (5, 33).
The interaction between different pathways of complement activation and tissue injury is poorly understood. We have
previously shown that C1q-dependent complement activation via the classical pathway contributes to the
pathogenesis of ethanol-induced liver injury (9); however, the relative contribution of the alternative pathway in ALD
is unknown. While Bykov et al. reported that chronic ethanol feeding in mice reduces the expression of FD and other
soluble regulators of the alternative pathway, including factor H and C4bp, these studies only provided associative
evidence for a role of the alternative pathway in ethanol-induced liver injury (6). In carbon tetrachloride-induced
hepatotoxity, FD is involved in the clearance of apoptotic cells from the site of injury (10). Complement inactivation
impairs the clearance of dying cells, leading to prolonged exposure to self-antigens and immune-mediated host
responses (25).
Complement is activated in liver from AH patients due in part to the alternative pathway; therefore, we tested the
hypothesis that FD contributes to the maintenance of tissue homeostasis during chronic ethanol by facilitating the
clearance of apoptotic cells. Making use of C57BL/6J [wild type (WT)], C1q-deficient (C1qa , lacking classical
pathway activation), complement protein 4-deficient (C4 , lacking both the classical and lectin pathways),
complement factor D-deficient-deficient (FD , lacking alternative pathway activation), and C1qa/FD  (lacking
both the classical and alternative pathways) mice, we have identified a novel role for FD in protecting the liver from
ethanol-induced steatosis, inflammation, accumulation of apoptotic hepatocytes, and initiation of profibrotic
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responses. These data demonstrate for the first time that FD, a key component of the alternative pathway, contributes
to complement activation in response to chronic ethanol feeding and that FD acts as a protective factor involved in
the resolution of ethanol-induced tissue injury.
MATERIALS AND METHODS
Animals
Female 8- to 10-wk-old C57BL/6J WT and knockout (KO) mice were used for all experiments. C57BL/6 mice were
obtained from Jackson Laboratories (Bar Harbor, ME). Complement knockout mice were obtained from the
following sources: C4  (14) and C1qa  (4) were provided by Dr. Michael Carroll (Harvard Medical School,
Boston, MA); FD  (56) and C1qa/FD  (53) were created by Dr. Gregory Stahl (Harvard Medical School). All KO
animals have been backcrossed to a C57BL/6 background and were bred in-house at the Cleveland Clinic.
Genotyping was routinely performed in complement KO mice using DNA extracted from tails with a DNeasy Blood
& Tissue Kit per the manufacturer’s instructions (Qiagen, Germantown, MD); primer sequences used for genotyping
were: C1qa  WT forward 5′-GGG GCC TGT GAT CCA GAC AG-3′, common reverse 5′-ACC AAT CGC TTC
TCA GGA CC-3′, and Mut forward 5′-GGG GAT CGG CAA TAA AAA GAC-3′; C4  WT forward 5′-ATA ACC
TGG GTC GGA CTT TGG-3′, common reverse 5′-TCT TCC GAA ACT GCT GGA TCC-3′, forward (NEO) 5′-TAC
CTG GGT ACT GCG GAA TGC-3′, reverse (NEO) 5′-AAG CCG GTC TTG TCG ATC AG-3′; FD : common
forward 5′-GAC GTG GAT CTG AGA TGC-3′, reverse (NEO) 5′-GGC CGA TCC CAT ATT GGC-3′, and reverse
5′-GGT TGC TCT CTG CAC ACA T-3′.
Ethanol Feeding Trials
All animal procedures were approved by the Cleveland Clinic Institutional Animal Care and Use Committee. Female
mice (C57BL/6J WT, C1qa , C4 , FD , and C1qa/FD ) were housed in standard microisolator cages (2
animals/cage). Age- and weight-matched mice were randomized into pair- and ethanol-fed groups, adapted to control
liquid diet for 2 days, and fed increasing concentrations of ethanol for 4 or 25 days as previously described (9). For
short-term studies, the ethanol-fed animals were acclimated to increasing concentrations of ethanol, 1% vol/vol (5.5%
kcal) for 2 days and 2% vol/vol (11% kcal) for 2 days, and is denoted as 11%, day 4. For chronic studies, the ethanol-
fed mice were acclimated to ethanol as follows: 1% vol/vol for 2 days, 2% vol/vol for 2 days, 4% vol/vol (22% kcal)
for 1 wk, 5% vol/vol (27% kcal) for 1 wk, and last 6% vol/vol (32% kcal) for 1 wk and is denoted as 32%, day 25.
Ethanol-fed mice were allowed ad libitum access to liquid diet. Control mice were pair fed a diet that received
isocalorically substituted maltose dextrins for ethanol. Plasma ethanol concentrations were measured in samples
collected 3 h into the feeding/dark cycle in C57BL/6J mice. Ethanol and pair-fed mice increased their body mass over
the course of the short-term (data not shown) and chronic (Table 1) studies. Lieber-DeCarli high-fat ethanol and
control diets were purchased from Dyets (catalog no.710260; Bethlehem, PA).
Sample Collection
At the conclusion of these experiments, mice were anesthetized, blood was taken from the posterior vena cava, and
livers were perfused with 0.9% saline via the hepatic portal vein. Livers were excised, and portions were stored in
RNAlater (Ambion, Austin, TX), fixed in formalin, or frozen in optimal-cutting temperature (OCT) compound
(Sakura Finetek, Torrance, CA) for histological analysis or snap-frozen in liquid nitrogen and stored at −80°C for
later analysis. Blood was transferred into EDTA-containing microtainer tubes (BD Biosciences), and plasma was
isolated following centrifugation and stored at −80°C until further analysis.
Acute Ethanol Exposure (Gavage) and Plasma Ethanol Measurements
Male mice were given a 6 g/kg dose of ethanol via an intragastric gavage. After the gavage (90 min), blood was
collected via tail nick in heparinized microhematocrit capillary tubes (Fisher Scientific, Pittsburgh, PA) and
centrifuged in a microcentrifuge with a microhematocrit rotor for 3 min. Plasma samples were assayed for ethanol
using a commercially available enzymatic assay kit (Sekisui Diagnostics, Lexington, MA). Mice were then
euthanized by inhalation of CO  and cervical dislocation.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling Staining
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Apoptotic DNA fragmentation was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) using the ApopTag Plus fluorescence in situ apoptosis detection kit (Millipore, Temecula, CA) on
paraffin-embedded liver sections according to the manufacturer’s protocol. Fluorescent images were captured on an
upright confocal microscope (Leica Microsystems, Buffalo Grove, IL). Percent TUNEL-positive nuclei of total nuclei
was determined by counting TUNEL-positive cells and 4,6-diamidino-2-phenylindole staining from three different
fields per slide using ImagePro Plus software (Media Cybernetics, Silver Spring, MD).
Liver Histology, Immunohistochemistry, and Immunofluorescence
For histological analysis, formalin-fixed tissues were paraffin embedded, sectioned, and stained with hematoxylin and
eosin. Paraffin-embedded liver sections were deparaffinized and stained with antibodies against tumor necrosis
factor-α (TNF-α, catalog no. 70R-TR008; Fitzgerald Industries, Acton, MA) (27, 39); M30, a caspase-dependent
cleavage product of cytokeratin 18 (M30CytoDEATH staining kit, catalog no.12140322001; Roche) (55), 4-
hydroxynonenal (4-HNE) protein adducts (kindly provided by Dr. Dennis Petersen, University of Colorado Anschutz
Medical Campus) (48); and PicroSirus Red (39). Frozen liver sections were mounted on glass slides, fixed with
paraformaldehyde, and stained for C3b/iC3b/C3c (catalog no. HM1065; Hycult Biotech, Plymouth Meeting, PA) and
C1q (catalog no. HM1044; Hycult Biotech) or Oil Red O as previously described (41, 47). Fluorescent images were
acquired using an upright confocal microscope (Leica Microsystems). Formalin and OCT samples are coded at the
time of collection for a blinded analysis; at least three images were acquired per tissue section, and semiquantification
of positive staining was performed using ImagePro Plus software. No specific immunostaining was seen in sections
incubated with PBS rather than the primary antibody (data not shown).
Biochemical Assays
Plasma samples were assayed for ALT and aspartate aminotransferase (AST) activity using the Sekisui Diagnostic
enzymatic assay kit according to the manufacturers protocol. Flash-frozen liver samples were used to quantify hepatic
triglyceride accumulation using a commercially available kit from Pointe Scientific (Lincoln Park, MI) per the
manufacturer’s protocol.
RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction
RNA was isolated from liver stored in RNAlater using RNeasy Mini kits per the manufacturer’s instructions (Qiagen,
Germantown, MD). Liver RNA (4 μg) was reverse transcribed and analyzed with PowerSYBR Quantitative Real-
Time Polymerase Chain Reaction kits (ThermoFisher, Grand Island, NY) on an Mx3000P analyzer (Stratagene, La
Jolla, CA). Relative mRNA expression was determined using the following gene-specific primers: human C1qR:
forward 5′-AGT GCC TGG ACC CTA GTC TG-3′, reverse 5′-GCT TGG AGA TGC ACG AGT TC-3′; human C3a
receptor (C3aR): forward 5′-CCC TAC GGC AGG TTC CTA TG-3′, reverse 5′-GAC AGC GAT CCA GGC TAA
TGG-3′; human C5aR: 5′-TCC TTC AAT TAT ACC ACC CCT GA-3′, reverse 5′-ACG CAG CGT GTT AGA AGT
TTT AT-3′; human C5a receptor-like 2 (C5L2): forward 5′-CTG TAT GCC GCC ATC TTC CT-3′, reverse 5′-TGG
CAT ACA TGG TCA GCA GG-3′; human 18S: 5′-CGG CTA CCA CAT CCA AGG AA-3′, reverse 5′-GCT GGA
ATT ACC GCG GCT-3′; mouse TNF-α: forward 5′-CCC TCA CAC TCA GAT CAT CTT CT-3′, reverse 5′-GCT
ACG ACG TGG GCT ACA G; mouse macrophage chemoattractant protein-1 (MCP-1/CCL2): forward 5′-AGG TCC
CTG TCA TGC TTC TG-3′, reverse 5′-TCT GGA CCC ATT CCT TCT TG-3′; mouse α-smooth muscle actin (α-
SMA): forward 5′-GTC CCA GAC ATC AGG GAG TAA-3′, reverse 5′-TCG GAT ACT TCA GCG TCA GGA-3′;
mouse collagen type I α -chain (Col1A1): forward 5′-ATG TTC AGC TTT GTG GAC CTC-3′, reverse 5′-CAG AAA
GCA CAG CAC TCG C-3′; mouse plasminogen activator inhibitor-1 (PAI-1): forward 5′-TTC AGC CCT TGC TTG
CCT C-3′, reverse 5′-ACA CTT TTA CTC CGA AGT CGG T-3′; mouse transforming growth factor-β1 (TGF-β):
forward 5′-TGA CGT CAC TGG AGT TGT ACG G-3′, reverse 5′-GGT TCA TGT CAT GGA TGG TGC-3′; mouse
18S: forward 5′-ACG GAA GGG CAC CAC CAG GA-3′, reverse 5′-CAC CAC CAC CCA CGG AAT CG-3′.
Statistical analyses were performed on the ∆C  values (average C  of gene of interest – average C  of 18S).
Patients
Liver tissue samples were provided by the National Institute on Alcohol Abuse
and Alcoholism-supported Clinical Resource for Alcoholic Hepatitis Investigations at Johns Hopkins University
(R24AA025017); all studies have been approved by Institutional Review Boards at Johns Hopkins Medical
Institutions. Tissue samples from explanted livers in patients with severe AH during liver transplantation or wedge
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biopsies from the donor livers (healthy control) were snap-frozen in liquid nitrogen and stored at −80°C.
Biochemical/clinical data for these samples have been reported previously (21). All samples are deidentified and
coded for blinded analysis.
All procedures conformed to the ethical guidelines of the 1975 Declaration of Helsinki and were
approved by the Ethics Committee of the Hospital Clinic of Barcelona; only patients with signed informed consent
were included. The study included patients admitted to the Liver Unit of the Hospice Clinic, Barcelona (2007–2009),
with clinical, analytical, and histological features of AH. Inclusion criteria for AH patients encompassed 1) active
alcohol consumption (>60 g/day) for at least 3 mo before admission, 2) increased aminotransferase levels (AST >
ALT), high γ-glutamyltranspeptidase and bilirubin serum levels, and 3) histological diagnosis of AH characterized by
the presence of hepatocellular damage, inflammatory infiltrate, and pericellular fibrosis as previously described (1,
24). A total of 36 patients with severe AH, indicated by Model for End-Stage Liver Disease scores >20, were
included in this study.
Serum from healthy control patients was obtained from the Northeast Ohio Alcohol Center at the Cleveland Clinic;
all procedures were approved by the Cleveland Clinic Institutional Review Board.
Liver Homogenates and Western Blotting
Protein lysates were made from frozen liver in lysis buffer containing: 0.5% Triton X-100, 20 mM HEPES (pH 7.4),
150 mM MgCl , 2 mM EGTA, 10 mM NaF, 1 mM PMSF, 1 mM Na (VO ) , 12.5 mM β-glycerol phosphate, 2 mM
DTT, and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Protein concentrations were determined
by the DC Protein Assay (Bio-Rad, Hercules, CA), and samples were denatured at 95°C in Laemmli buffer. Samples
were separated on SDS-PAGE gels, transferred to polyvinylidene fluoride membranes with a semidry transfer
apparatus (Bio-Rad), and blocked in 3% bovine serum albumin. Membranes were probed with antibodies specific for
CYP2E1 (catalog no. AB1252; EMD Millipore, Billerica, MA), heat shock cognate 71 kDa protein (HSC70, catalog
no. sc-7298; Santa Cruz Biotechnologies, Carlsbad, CA), C3 (catalog no. 55033; MP Biomedicals, Solon, OH), and
complement factor B (catalog no. AF2739; R&D Systems, Minneapolis, MN). Horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were applied, and membranes were developed
using Immobilon Western Developing reagents (Millipore). Chemiluminescence was visualized using an Eastman
Kodak Image Station 4000R (Rochester, NY). Arbitrary density of immunopositive bands was quantified using
ImageJ software.
Enzyme-Linked Immunosorbant Assay
Anaphylatoxin fragment of C5 (C5a) enzyme-linked immunosorbant assay (ELISA) was performed in patient serum
according to the manufacturer’s protocol (human C5a ELISA; Hycult Biotech).
Statistical Analysis
Values reported are means ± SE. Data were collected from several different feeding trials. The data were analyzed by
the general linear models procedure (SAS, Carey, IN) followed by least-square means analysis of differences between
groups, blocking for experiment effects when data from more than one experiment were used in any given dataset.
Data were log transformed to obtain a normal distribution, if necessary.
RESULTS
Complement is Activated in Patients with Severe AH
Activation of complement contributes to mALD; however, complement activation in patients with ALD has not been
extensively studied. Complement activation products were measured in liver explants from AH patients or wedge
biopsies from control livers (Fig. 1). In liver, expression of FB and the active cleavage fragment fBb, but not fBa, was
increased in AH patients compared with controls (Fig. 1, A and B). Cleavage of C3 into C3b, iC3b, and C3c
fragments was increased in AH liver (Fig. 1, C and D). Expression of C1q receptor (C1qR) and the anaphylatoxin
receptors C3aR, C5aR, and C5L2 was increased in AH liver (Fig. 1E). Furthermore, circulating anaphylatoxin C5a
was increased in patients with AH compared with healthy controls (Fig. 1F). Taken together, these data provide
evidence for activation of complement via the classical and alternative pathways in livers of AH patients.
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FD  Mice Have Increased Chronic Ethanol-Induced Liver Injury
C1q, C3, and C5 are required for the progression of ethanol-induced liver injury in mice (5, 9, 33, 40). While aberrant
complement activation can contribute to tissue injury, failure to mount an appropriate activation response is known to
negatively affect tissue homeostasis and maintenance. Therefore, in an effort to better understand the involvement of
specific pathways of complement activation and the progression of ethanol-induced liver injury, C57BL6/J WT,
C1qa , C4 , FD , and C1qa/FD  mice were fed ethanol-containing diets for 25 days (32%, day 25). Diet
consumption was monitored throughout the study; C4  and FD  consumed 10–12% less diet compared with WT,
C1qa , and C1qa/FD  mice (Table 1). Plasma ethanol levels in WT mice increased when the diet contained 4%
ethanol (vol/vol) or higher, reaching ~50 mM after 6% (vol/vol) ethanol (Fig. 2A). After 25 days, plasma ALT and
AST activities were increased in WT mice compared with pair-fed controls. Chronic ethanol-induced increases in
ALT/AST activities were lower in C4  and C1qa/FD  mice than in WT mice (Fig. 2, B and C), similar to the
protection previously reported in C1qa  mice (9). In contrast, increases in ALT and AST were higher in FD  mice
compared with WT mice (Fig. 2, B and C). Hepatic triglycerides were increased in ethanol-fed WT mice compared
with pair-fed controls (Fig. 2D). C4  and C1qa/FD  mice were protected from chronic ethanol-induced increases
in hepatic triglyceride accumulation, congruent with C1qa  mice (9). Hepatic triglycerides were increased in FD
compared with WT mice (Fig. 2D). Oil Red O staining of neutral lipid was consistent with the biochemical
assessment of triglyceride (Fig. 2E). Lipid accumulated in the periportal (zone 1) and midzonal (zone 2) regions of
WT mice liver after chronic ethanol feeding (Fig. 2F). In C1qa , C4 , and C1qa/FD  mice, there was minimal
lipid accumulation. FD  mice had extensive steatosis in both the periportal and midzonal regions of the lobule after
ethanol feeding for 25 days. Taken together, these data demonstrate that FD protects against hepatic lipid
accumulation and hepatocyte injury following chronic ethanol feeding.
Ethanol Metabolism Was Not Different Between Genotypes
To ensure that differences in susceptibility to ethanol-induced injury were not because of differences in ethanol
metabolism, plasma ethanol was quantified following an acute gavage of ethanol. Plasma ethanol levels were
measured 90 min after the gavage and ranged from 104 to 112 mM (Table 2); no differences between WT, C1qa
(9), C4 , FD , or C1qa/FD  mice were observed. Mice that received saline as a control had no detectable levels
of ethanol (data not shown). These data suggest that any differences in liver injury between genotypes are
independent of differences in ethanol metabolism.
C1qa  and C4  Mice Are Protected From, While FD  Mice Have Increased, Hepatic
Inflammation After Chronic Feeding
Ethanol activates cellular components of the innate immune system, including Kupffer cells, to secrete
cytokines/chemokines; TNF-α is a key proinflammatory cytokine that contributes to liver injury during ethanol
exposure. In pair-fed WT, C1qa , and C4  mice, TNF-α expression assessed by immunohistochemistry was low
and localized near the portal vein (Fig. 3, A and B). FD  and C1qa/FD  pair-fed mice had slightly higher
expression of TNF-α in the liver, in both the periportal and centrilobular regions in the liver. In WT mice, ethanol
feeding increased TNF-α expression throughout the lobule, with punctate expression along the sinusoids and
dispersed expression near the centrilobular region (zone 3) in cells with the morphological appearance of hepatocytes
(Fig. 3A). In contrast, TNF-α expression was lower in C1qa , C4 , and C1qa/FD  mice. TNF-α expression was
more pronounced in ethanol-fed FD  mice, with marked deposition near the centrilobular region. Consistent with
increased expression of immunoreactive TNF-α, expression of TNF-α and MCP-1/CCL2 mRNA was increased in
liver of WT mice after chronic ethanol feeding compared with pair-fed controls (Fig. 3, C and D). C1qa , C4 ,
and C1qa/FD  mice were protected from ethanol-induced increases in TNF-α and MCP-1 mRNA. In contrast, FD
 mice had increased expression of proinflammatory cytokines after ethanol feeding compared with WT mice (
Fig. 2, C and D).
Hepatic 4-HNE Protein Adducts Were Increased in FD  Mice After Chronic Ethanol Feeding
Lipid peroxidation is characteristic of ethanol-induced liver injury; oxidative stress is induced both because of ethanol
metabolism via CYP2E1 and increased expression of inflammatory mediators (49). The accumulation of 4-HNE
adducts, a well-characterized by-product of lipid peroxidation and indicator of cellular oxidative stress, was increased
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in WT mice after chronic ethanol feeding compared with pair-fed controls (Fig. 4, A and B). Ethanol-fed FD  mice
had increased hepatic 4-HNE adducts compared with WT mice (Fig. 4, A and B). The expression of CYP2E1 protein
was increased in WT and FD  mice after chronic ethanol feeding, with no difference between genotypes (Fig. 4C).
These data suggest that increased oxidative stress was likely because of an increased inflammatory milieu in FD
mice rather than an increased rate of ethanol metabolism via CYP2E1.
Complement Activation Was Impaired in FD  Mice After Chronic, But Not Short-Term, Ethanol
Feeding
C1q accumulates in the liver after both short-term and chronic ethanol feeding, consistent with a role of C1qa in
chronic ethanol-induced liver injury (9). Here we find that FD was not required for C1q accumulation in liver in
response to ethanol feeding. After short-term ethanol feeding, immunoreactive C1q increased in the sinusoids of WT
and FD  mice compared with WT pair-fed controls (Fig. 5, A and B). C1q deposition was also increased in ethanol-
fed WT and FD  mice compared with WT pair-fed controls after chronic ethanol (Fig. 5, A and C).
Cleavage of C3 in the liver was assessed by immunofluorescence with an antibody directed against the neoepitopes of
C3b/iC3b/C3c (referred to as C3b) that are revealed once C3 is cleaved (26). After short-term ethanol feeding,
deposition of C3b increased in the hepatic sinusoids of WT and FD  mice, but not C1qa  (9), C4 , or
C1qa/FD  mice (Fig. 6, A and B) compared with pair-fed controls. After chronic ethanol, C3b deposition shifted to
the parenchyma in WT mice but was absent in all other genotypes (9) (Fig. 6, A and C). These data suggest that,
while early ethanol-induced activation of complement is C1q dependent (9), complement activation after
chronic/high-dose ethanol feeding is both C1q (9) and FD dependent, with FD likely serving to amplify the activation
via C1q.
FD  Mice Accumulated More Apoptotic Hepatocytes After Chronic Ethanol Feeding
Hepatocyte apoptosis is associated with the progression of ethanol-induced liver injury, driven, at least in part, by
increased inflammatory mediators and oxidant stress within the parenchyma. Accumulation of apoptotic cell bodies
in the liver occurs via increased apoptosis and/or impaired clearance (2, 10). Given the enhanced inflammation and
oxidative stress evident in the FD  mice, as well as the decreased deposition of C3b, an important opsonin for the
clearance of apoptotic cells, we predicted that FD  mice would accumulate more apoptotic hepatocytes in response
to chronic ethanol. After short-term ethanol feeding, WT and FD  mice accumulated more TUNEL-positive nuclei
in the liver compared with pair-fed controls (Fig. 7, A and B). After chronic ethanol feeding, FD  had even more
TUNEL-positive cells than WT mice (Fig. 7, A and C). M30 recognizes the caspase-cleavage product of cytokeratin-
18, a marker of hepatocyte apoptosis (55) and component of Mallory-Denk bodies (42). M30-positive hepatocytes
were increased in ethanol-fed WT mice and further increased in FD  mice (Fig. 7, D and F).
Fibrotic Responses Were Induced In Ethanol-Fed FD  Mice
Because of their proximity to hepatocytes, hepatic stellate cells (HSCs) can engulf apoptotic bodies, stimulating
fibrogenic activity (7). Because FD  mice had increased accumulation of apoptotic hepatocytes after chronic
ethanol feeding, combined with the failure to activate complement, an important pathway for clearance of apoptotic
cells (52), we predicted that FD  mice have an increased activation of HSCs with associated expression of
profibrogenic markers in the liver after chronic ethanol feeding. PicroSirius Red staining was modestly increased in
ethanol-fed WT mice, without increases in the expression of Col1A1, TGF-β, PAI-1, or α-SMA mRNA (Fig. 7, E, G,
and H). More robust chicken-wire fibrosis was observed in ethanol-fed FD  mice that coincided with an
upregulation of Col1A1, TGF-β, and PAI-1, but not α-SMA, mRNA (Fig. 7, E, G, and H). Taken together, these data
indicate that FD  mice have increased accumulation of apoptotic cells and/or impaired clearance of cellular debris
that was associated with fibrogenic responses in the liver after chronic ethanol feeding.
DISCUSSION
Complement plays a fundamental role in both innate and adaptive immunity primarily as a defense mechanism
against infections. Consistent with this function, deficiencies/defects in the complement cascade can result in
increased susceptibility to infection and/or complement-mediated tissue damage (8). Complement is implicated as a
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major driver of alcohol-induced liver injury in mice (5, 9, 27, 33, 40, 47). Although C1q-mediated complement
activation contributes to ethanol-induced liver injury in mice (9), the role of other pathways of complement activation
has not yet been explored in the context of ALD. Here, for the first time, we identified a crucial role of FD, a key
component of the alternative pathway, in chronic ethanol-induced complement activation in mice. Importantly, FD is
a protective factor that is involved in hepatocyte injury (ALT/AST/triglyceride) and hepatic inflammation. Moreover,
the ability of FD to amplify complement is necessary for appropriate clearance of apoptotic cells and maintenance of
tissue homeostasis after chronic ethanol feeding (Fig. 8).
While complement activation contributes to mALD, less is known about the patterns of complement activation in
ALD patients. Our data reveal that complement is activated in explants from liver of AH patients, due in part to the
alternative pathway, as evidenced by the cleavage of FB. Our data are consistent with Shen et al. who observed
increased immunoreactivity of C1q, as well as C3, C5, and C5aR, in liver biopsies from AH patients (46).
Collectively, these data indicate that both the classical and alternative pathways of complement contribute to local
activation of complement in the liver in ALD. Our data in mALD suggest that classically vs. alternatively activated
complement may have differential impact on progression of ALD whereby the classical pathway contributes to
nonresolving inflammation and the alternative pathway promotes resolution/wound healing via the clearance of
damaged tissue/cells (Fig. 8). Because the alternative pathway is protective in mALD, we hypothesize that increased
activation of complement via the alternative pathway is an adaptive mechanism to promote resolution of tissue injury;
however, during end-stage liver disease, FD-dependent amplification of complement is not sufficient to encourage
recovery. Understanding patterns of complement activation may be a powerful diagnostic tool and therapeutic target
in patents with ALD.
The interaction between classical and alternative pathway activation in response to tissue injury is complex and
poorly understood. Although complement activation can occur via the classical, lectin, and alternative pathways,
engagement of the alternative pathway is required to cause tissue injury in vivo in several disease models (51). For
example, in models of systemic lupus erythematosus (SLE), FB  and FD  mice, lacking the alternative pathway,
are protected from C3 glomerulonephritis (13), whereas C4  mice, deficient in both classical and lectin pathways,
are more diseased (34). This protective role for C4 and proinjury role for the alternative pathway also holds true in
models of rheumatoid arthritis and renal ischemia-reperfusion injury (51). The influence of the alternative pathway is
likely related to its ability to amplify complement activation; amplification by the alternative pathway may account
for up to 80% of the C5a and membrane attack complex generated by classical pathway activation (18, 51).
In contrast to the injurious role of FD and protection via C4 described in SLE, rheumatoid arthritis, and renal injury,
here we find that the contributions of FD and C4 are reversed in chronic ethanol-induced injury. FD  mice had
greater ethanol-induced injury, and C4  mice, deficient in both the classical and lectin pathways, were protected
from ethanol-induced liver injury. The protection in C4  mice is consistent with the protection of C1qa  mice
from ethanol-induced liver injury (9). Together, the impact of C4 and C1qa deficiency implicates an important role
for the classical pathway in ethanol-induced liver injury. Interestingly, C1qa/FD  mice were protected from injury,
indicating that C1q is required for ethanol-induced liver injury in FD  mice.
It is interesting to speculate that the differential contributions of C4 and FD to inflammation may be tissue specific,
with a protective role for FD in the liver compared with other diseases. In patients with nonalcoholic steatohepatitis
(NASH), activation of complement is associated with the accumulation of both classical and lectin components (35),
as well as activation of the alternative pathway (45). Hepatic properdin, a positive regulator of the alternative
pathway, and C3 activation fragments were positively correlated with lobular inflammation in NASH, whereas
hepatic factor H, a negative regulator of alternative activation, mRNA was downregulated (45). It will be important
for future studies to investigate C4  and FD  mice in high-fat diet-induced models of NASH to more clearly
define the role of FD in either promotion or protection from metabolic liver injury.
The dynamics of complement activation in the liver were complex, differing after the dose and duration of ethanol
exposure. Hepatic C1q and C3b deposition occurs after short-term low-dose ethanol feeding in mice; this early
complement activation is C1q dependent (5, 9), but FD independent, since C3b accumulated in the liver of FD
mice after short-term ethanol feeding. In contrast, C3b deposition after chronic ethanol exposure was both C1q and
FD dependent (Ref. 9 and Fig. 6), suggesting that FD-dependent amplification of complement is necessary, but not
sufficient, for C3 activation after chronic/high-dose ethanol; C1q is not sufficient to sustain complement activation.
−/− −/−
−/−
−/−
−/−
−/− −/−
−/−
−/−
−/− −/−
−/−
/
Another characteristic of FD  mice was elevated steatosis; the mechanism for this is not known. Complement is
implicated in the cross talk between the immune system and metabolism in adipose tissue and liver (31), both
significant targets of alcohol (54). FD, also known as adipsin, is mainly produced by adipocytes and is an adipokine
with both direct and indirect immunometabolic properties (23). Acylation-stimulating protein (ASP/C3adesArg), a
downstream degradation product of C3, can stimulate triglyceride synthesis and glucose transport in adipocytes
through the actions of the C3a receptor C5L2 (20, 32). Indeed, FD is sufficient to induce the expression of PPARγ, a
transcription factor involved in assimilation of lipid, in preadipocytes (50). Modulation of the adipose-liver axis is
one potential mechanism by which FD could protect from ethanol-induced steatosis.
A major hallmark of ethanol-induced liver injury is apoptosis. Complement contributes to the resolution of
inflammation by promoting clearance of apoptotic cells and immune complexes through the cooperative actions of its
soluble pattern recognition molecules, like C1q, opsonins, and receptors (15, 36, 52). Following injury and activation
of complement, C3b is released and deposited on both apoptotic and necrotic cells, facilitating phagocytosis and
clearance of the damaged cells (52). Because FD  mice had decreased deposition of C3b/iC3b/C3c in the liver after
chronic ethanol feeding in mice, they likely had impaired opsonization of apoptotic bodies in the parenchyma. Cells
that undergo apoptosis initially maintain membrane integrity, ensuring that cellular contents are confined and properly
ingested by phagocytes. However, if clearance of apoptotic bodies is impaired or delayed, these cells can undergo a
process known as secondary necrosis, an event that leads to membrane permeability and eventual leakage of
proinflammatory macromolecules (38, 43). Multiple pathways contribute to the clearance of apoptotic/necrotic debris
from the liver in response to carbon tetrachloride-induced injury, including FD and plasminogen activators; the
absence of these clearance pathways contributes to a continued exacerbation of inflammation and injury (2, 10).
Increased accumulation of apoptotic cells within the parenchyma of FD  mice after chronic ethanol feeding is one
potential contributing factor to elevated inflammation, liver injury, and upregulation of profibrotic responses observed
in FD  mice.
Whether FD  mice have increased apoptosis or impaired clearance of apoptotic cells after chronic ethanol feeding
remains unclear. Indeed, inflammatory mediators contribute to hepatocyte dysfunction, including apoptosis and
necroptosis, to perpetuate tissue injury. Failure to activate complement is linked to increased sensitization of
hepatocytes to ethanol; signaling via C5aR on hepatocytes is cytoprotective from ethanol/TNF-α-induced cytotoxicity
(27). Because FD  mice had increased cytokine expression and elevated 4-HNE adducts, as well as impaired
alternative pathway-driven complement activation after chronic ethanol feeding, it is likely that both increased
apoptosis and impaired clearance is occurring.
In summary, complement plays a critical role in the development of alcohol-induced liver injury. In patients with
severe AH, complement is activated in liver, at least in part via the alternative pathway. Our findings in mALD
suggest FD promotes the clearance of apoptotic cells during the development of alcohol-induced liver injury.
Moreover, this work suggests that FD is protective in maintaining tissue homeostasis via its opsonization function
after ethanol feeding in mice, in contrast to driving pathological complement activation via its potent amplification
loop. Finally, these data highlight the twofold purpose of complement in inflammatory and protective responses and
suggest that inappropriate complement activation likely delays the clearance of apoptotic cells and impairs
healing/recovery in the liver in response to chronic ethanol.
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Figures and Tables
Table 1.
Body weights and food intakes for mice allowed free access to chronic ethanol-containing diets for 25 days
(1% ethanol for 2 days, 2% ethanol for 2 days, 4% ethanol for 1 wk, 5% ethanol for 1 wk, and 6% ethanol for
1 wk)
Chronic Ethanol Model (32%, day 25)
Pair fed EtOH fed EtOH fed
Genotype Initial body wt,
g
Final body wt,
g
Initial body wt,
g
Final body wt,
g
Average daily food intake,
ml/cage
C57BL/6J 18.10 ± 0.27 22.58 ± 0.62 † 18.36 ± 0.29 21.87 ± 0.50 † 21.83 ± 1.25
C4 16.90 ± 0.68 19.05 ± 1.29 † 17.10 ± 0.48 19.62 ± 0.52 † 19.31 ± 1.13
FD 17.11 ± 0.51 20.05 ± 0.88 † 17.60 ± 0.32 20.03 ± 0.43 † 18.88 ± 1.03
C1qa/FD 16.32 ± 0.65 20.31 ± 0.89 † 17.18 ± 0.53 20.10 ± 0.64 † 21.16 ± 1.29
Values are means ± SE. C4 , complement protein 4-deficient; FD , complement factor FD-deficient; C1qa/FD ,
complement component 1, Q subcomponent FD deficient. Body weights and diet intakes after chronic feeding (day 25) for C1qa-
deficient mice have been previously reported (8).
Data for the wild type are combined values from 2 independent feeding trials, n = 8–12 animals/group.
Data are from one independent feeding trial, n = 4–6 animals/group. Values with different superscript letters are significantly
different from each other between ethanol-fed genotypes (P < 0.05).
Values are significantly different from initial body weights within each genotype (P < 0.05).
* a a a
−/−§ b b b
−/−§ b b b
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Fig. 1.
Complement is activated in liver explants and peripheral serum of patients with alcoholic hepatitis (AH). Liver lysates were prepared
from liver explants from AH patients or wedge biopsies from control livers [healthy controls (HC)], and proteins were separated by
SDS-PAGE. Factor B and activation fragments fBb and fBa (A and B) and complement protein 3 (C3), C3 cleavage fragments (C3b,
iC3b, C3c), and heat shock cognate 71 kDa protein (HSC70, loading control) (C and D) were measured by Western blot. Relative
expression is denoted as arbitrary units of density. Values represent means ± SE; n = 5 mice/group. E: expression of complement
component 1, Q subcomponent receptor (C1qR), anaphylatoxin fragment of C3 (C3a) receptor (C3aR), anaphylatoxin fragment of C5
(C5a) receptor (C5aR), and C5a receptor-like 2 (C5L2) was detected in AH liver or wedge biopsies from HC by Real-Time
Polymerase Chain Reaction. Data are relative fold change over wedge biopsies from HC. Values represent means ± SE; n = 5/group. F:
circulating C5a was measured in plasma. Values represent means ± SE; n = 5 HC and n = 36 AH.

Fig. 2.
Open in a separate window
Complement factor D-deficient (FD ) mice had pronounced liver injury and steatosis after chronic ethanol (EtOH) feeding. Wild-
type (WT), complement component 1, Q subcomponent-deficient (C1qa ), complement protein 4-deficient (C4 ), FD , and
C1qa/FD  were allowed free access to EtOH [32%, day (d) 25] or pair-fed control diets. A: plasma EtOH concentrations were
measured 3 h into the feeding/dark cycle from WT mice. Values represent means ± SE; n = 3 for pair-fed and 6–10 for EtOH-fed mice.
Values with different symbols are significantly different from each other. Alanine transaminase (ALT, B) and aspartate
aminotransferase (AST, C) activity was measured in plasma. D: hepatic triglyceride content was measured in whole liver tissue. E:
frozen liver sections were stained with Oil Red O. Images were acquired using a ×20 objective. F: paraffin-embedded liver sections
were deparaffinized followed by staining with hematoxylin and eosin (H&E). Images were acquired using ×10 and ×20 objectives.
Periportal (zone 1), midzonal (zone 2), and centrilobular (zone 3) regions are indicated in ×20 images. Values represent means ± SE;
data for WT are combined values from 2 independent feeding trials, n = 8–12 animals/group. C1qa , C4 , FD , and C1qa/FD
are from one independent feeding trial; n = 4–6 animals/group. Values with different superscripts are significantly different from each
other (P < 0.05). Biochemical measures of injury for C1qa  mice have been previously reported (9).
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−/− −/− −/−
−/−
−/− −/− −/− −/−
−/−
Table 2.
Plasma ethanol concentration in WT, C4 , FD , and C1qa/FD  mice 90 min after a 6 g/kg oral gavage
Genotype: C57BL/6J C4 FD C1qa/FD
Plasma ethanol, mM 104.7 ± 5.1 107.4 ± 7.1 112.2 ± 14.5 104.5 ± 8.6
Data are means ± SE; n = 3–5 animals per group. C4 , complement protein 4-deficient; FD , complement factor FD-deficient;
C1qa/FD , complement component 1, Q subcomponent/FD deficient. Plasma ethanol concentrations after acute gavage from
C1qa-deficient mice have been previously reported (8).
−/− −/− −/−
−/− −/− −/−
−/− −/−
−/−
Fig. 3.
Complement component 1, Q subcomponent (C1q) and complement protein 4 (C4) contributed to, while complement factor D (FD)
protected from, chronic ethanol (EtOH)-induced hepatic inflammation. Wild-type (WT), C1q-deficient (C1qa ), complement protein
4-deficient (C4 ), complement factor D-deficient (FD ), and C1q/FD  were allowed free access to EtOH [32%, day (d) 25] or
pair-fed control diets. A: paraffin-embedded liver sections were deparaffinized followed by immunodetection of tumor necrosis factor-
α (TNF-α). Nuclei were counterstained with hematoxylin. All images were acquired using a ×20 objective. B: TNF-α-stained areas
were quantified from at least three images per slide using Image-Pro Plus software. Expression of TNF-α (C) and macrophage
chemoattractant protein-1 (MCP-1/CCR2, D) mRNA was detected in mouse livers using Quantitative Real-Time Polymerase Chain
Reaction. Values with different alphabetical superscripts were significantly different from each other (P < 0.05). Values represent
means ± SE; n = 4–8 pair-fed and 6–12 EtOH-fed mice.
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Fig. 4.
Complement factor D-deficient (FD ) mice were more susceptible to oxidative stress. Wild-type (WT) and FD  mice were
allowed free access to ethanol [EtOH, 32%, day (d) 25] or pair-fed control diets. A: paraffin-embedded liver sections were
deparaffinized, and 4-hydroxynonenal adducts were detected by immunohistochemistry. B: positive staining was quantified in ×10
images from at least three images per slide using Image-Pro Plus software. C: liver lysates were prepared and proteins were separated
by SDS-PAGE. CYP2E1 and heat shock cognate 71 kDa protein (HSC70, loading control) were measured by Western blot. Relative
expression is denoted as arbitrary units of density. Values represent means ± SE; values with different superscripts were significantly
different from each other (P < 0.05); n = 4 pair-fed and 3–6 EtOH-fed mice.
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Fig. 5.
Hepatic complement component 1, Q subcomponent (C1q) deposition was increased in wild-type (WT) and complement factor D-
deficient (FD ) mice after short-term and chronic ethanol (EtOH) feeding. WT and FD  mice were allowed free access to EtOH
[11%, day (d) 4 and 32%, day 25] or pair-fed control diets. A: frozen liver sections were immunostained for C1q deposition.
Representative images for C1q deposition in pair-fed controls for chronic 25-day studies were similar to 4 days (data not shown). All
images were acquired using a ×40 oil immersion objective. Positive immunofluorescence after short-term (B) and chronic (C) EtOH
feeding was quantified from at least three images per slide using Image-Pro Plus software. Values represent means ± SE; values with
different superscripts were significantly different from each other (P < 0.05); n = 4 pair-fed and 6 EtOH-fed mice.
−/− −/−
Fig. 6.
Open in a separate window
Hepatic C3b deposition was impaired in complement factor D-deficient (FD ) mice after chronic, but not short-term, ethanol
(EtOH) feeding. WT, complement component 1, Q subcomponent-deficient (C1qa ), complement protein 4-deficient (C4 ), FD
, and C1qa/FD  mice were allowed free access to EtOH [11%, day (d) 4 and 32%, day 25] or pair-fed control diets. A: frozen liver
sections were immunostained for C3b/iC3b/C3c deposition. Representative images for C3b/iC3b/C3c deposition in pair-fed controls
for chronic 25-day studies were similar to 4 days (data not shown). All images were acquired using a ×40 oil immersion objective.
Positive immunofluorescence after short-term (B) and chronic (C) EtOH feeding was quantified for C4 , FD , and C1qa/FD
mice from at least three images per slide using Image-Pro Plus software. Positive immunofluorescence for C1qa  has been
previously reported (9). Values represent means ± SE; values with different superscripts were significantly different from each other (P
< 0.05); n = 4–8 pair-fed and 5–12 EtOH-fed mice.
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Fig. 7.
Open in a separate window
Complement factor D-deficient (FD ) mice had increased accumulation of apoptotic cells and initiation of profibrotic responses
after chronic ethanol (EtOH) feeding. Wild-type and FD  mice were allowed free access to EtOH [11%, day (d) 4 and 32%, day 25]
or pair-fed control diets. Paraffin-embedded livers were deparaffinized followed by immunohistochemistry. All images were
quantified from at least three images per slide. A: apoptotic cells were visualized in paraffin-embedded liver sections. B and C:
terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells were enumerated and expressed as a
percent of the total 4,6-diamidino-2-phenylindole (DAPI) nuclei/×40 field. D: apoptotic hepatocytes were visualized with a caspase-
dependent cleavage product of cytokeratin 18. F: M30-positive cells, indicated by open arrows, were counted and represented as M30-
positive cells/×20 field. E: extracellular matrix was visualized with PicroSirius Red. Black arrows indicate positive staining within the
parenchyma. G: PicroSirius Red-positive staining was quantified using Image-Pro Plus software and normalized to the total area per
×10 field. H: expression of α-smooth muscle actin (α-SMA), collagen type I α -chain (Col1A1), transforming growth factor-β1 (TGF-
β), and plasminogen activator inhibitor-1 (PAI-1) was detected in mouse livers using Quantitative Real-Time Polymerase Chain
Reaction. Values represent means ± SE; values with different superscripts were significantly different from each other (P < 0.05); n = 4
pair-fed and 3–6 EtOH-fed mice. *Significantly different from genotype pair-fed controls (P < 0.05).
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Fig. 8.
Open in a separate window
Complement activation and involvement during alcoholic liver disease. In mouse models of ALD, ethanol (EtOH) induces the
activation of complement via complement component 1, Q subcomponent (C1q), leading to the cleavage of complement protein 3
(C3) into the anaphylatoxin fragment of C3 (C3a) and C3b. The potent anaphylatoxins C3a and C5a act on cognate receptors (C3aR
and C5aR) on resident hepatic macrophages (Kupffer cells) to initiate the transcription of proinflammatory mediators. During chronic
EtOH, amplification of complement via the alternative pathway is required to provide essential opsonins (C3b/iC3b/C3c) on the
surface of damaged cells in the liver, facilitating clearance of debris and allowing for resolution and repair. TNF-α, tumor necrosis
factor-α; IL-6, interleukin-6; MCP-1, macrophage chemoattractant protein-1; FB, complement factor B; FD, complement factor D; C4,
complement protein 4; C2, complement protein 2; C4b, 2a, C3 convertase; fBb, FB activation fragment b; fBa, FB activation fragment
a. Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2018. All Rights Reserved.
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